文献速递前列腺癌

Apa-RP研究中皮疹管理指南对接受阿帕他胺治疗的高危局限性前列腺癌患者的影响

Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-07-05

Apa-RP研究向所有入组患者提供预设的皮疹管理指南,并将皮疹相关安全性数据与SPARTAN和TITAN研究进行描述性比较。结果显示Apa-RP患者的皮疹相关结局优于SPARTAN和TITAN患者。结论认为提高警惕和主动管理可能降低阿帕他胺治疗期间皮疹的发生率、严重程度和持续时间。

要点

  • Apa-RP研究向所有患者提供预设的皮疹管理指南,概述推荐的皮肤护理实践。
  • Apa-RP患者的皮疹相关结局优于SPARTAN和TITAN研究患者。
  • 提高警惕和主动管理可能降低阿帕他胺治疗期间皮疹的发生率、严重程度和持续时间。

核心结论

  • 提高警惕和主动管理可能降低阿帕他胺治疗期间皮疹的发生率、严重程度和持续时间。

研究设计与样本

  • Apa-RP研究(NCT04523207)向所有入组患者提供预设的皮疹管理指南,并将皮疹相关安全性数据与SPARTAN和TITAN研究进行描述性比较。

主要发现

  • Apa-RP患者的皮疹相关结局优于SPARTAN和TITAN研究患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes. SUBJECTS/METHODS: A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN. RESULTS: Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN. CONCLUSIONS: Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Shore N, Hafron J, Saltzstein D, et al. Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study. Prostate Cancer Prostatic Dis. 2024. PMID: 38969791. doi:10.1038/s41391-024-00858-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。